Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 12 | 2024 | 600 | 5.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 4 | 2025 | 56 | 3.470 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2025 | 51 | 1.780 |
Why?
|
| Cardiomyopathies | 3 | 2024 | 120 | 1.670 |
Why?
|
| Cardiovascular Diseases | 7 | 2023 | 821 | 1.620 |
Why?
|
| Blood Pressure | 9 | 2024 | 521 | 1.500 |
Why?
|
| Antihypertensive Agents | 4 | 2021 | 172 | 1.400 |
Why?
|
| Dietary Approaches To Stop Hypertension | 4 | 2023 | 13 | 1.370 |
Why?
|
| Myocardial Ischemia | 2 | 2025 | 109 | 1.130 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2024 | 34 | 1.120 |
Why?
|
| Pre-Eclampsia | 3 | 2024 | 85 | 1.100 |
Why?
|
| Cardiac Rehabilitation | 2 | 2025 | 67 | 1.090 |
Why?
|
| Telemedicine | 3 | 2025 | 335 | 0.980 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 153 | 0.970 |
Why?
|
| Contraception | 2 | 2022 | 65 | 0.940 |
Why?
|
| Ventricular Premature Complexes | 1 | 2024 | 21 | 0.920 |
Why?
|
| Echocardiography | 5 | 2024 | 459 | 0.910 |
Why?
|
| Pregnancy | 10 | 2025 | 2355 | 0.890 |
Why?
|
| Heart Failure | 4 | 2023 | 867 | 0.880 |
Why?
|
| Mobile Applications | 1 | 2025 | 130 | 0.830 |
Why?
|
| Contraceptive Effectiveness | 1 | 2022 | 3 | 0.800 |
Why?
|
| Tachycardia, Ventricular | 1 | 2024 | 118 | 0.800 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 160 | 0.800 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 11 | 0.790 |
Why?
|
| Patient Compliance | 1 | 2024 | 371 | 0.790 |
Why?
|
| Female | 32 | 2025 | 30914 | 0.770 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2021 | 23 | 0.750 |
Why?
|
| Humans | 42 | 2025 | 59512 | 0.720 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 117 | 0.720 |
Why?
|
| Adult | 20 | 2025 | 15776 | 0.690 |
Why?
|
| Qualitative Research | 1 | 2024 | 618 | 0.690 |
Why?
|
| Cardiology | 1 | 2022 | 164 | 0.680 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 14 | 0.660 |
Why?
|
| Young Adult | 8 | 2025 | 4326 | 0.640 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 169 | 0.600 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 122 | 0.540 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 2475 | 0.470 |
Why?
|
| Risk Factors | 8 | 2025 | 5014 | 0.470 |
Why?
|
| Health Surveys | 1 | 2015 | 306 | 0.450 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2023 | 52 | 0.450 |
Why?
|
| Middle Aged | 16 | 2024 | 16278 | 0.420 |
Why?
|
| United States | 10 | 2024 | 7530 | 0.410 |
Why?
|
| Stroke Volume | 3 | 2023 | 321 | 0.390 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 167 | 0.380 |
Why?
|
| Vital Capacity | 1 | 2011 | 72 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 705 | 0.370 |
Why?
|
| Sinusitis | 1 | 2011 | 27 | 0.370 |
Why?
|
| Forced Expiratory Volume | 1 | 2011 | 148 | 0.360 |
Why?
|
| Peptide Fragments | 3 | 2023 | 353 | 0.360 |
Why?
|
| Endoscopy | 1 | 2011 | 97 | 0.350 |
Why?
|
| Cystic Fibrosis | 1 | 2011 | 108 | 0.350 |
Why?
|
| Ventricular Remodeling | 2 | 2021 | 80 | 0.330 |
Why?
|
| Gout | 3 | 2015 | 53 | 0.320 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 783 | 0.310 |
Why?
|
| Heart | 3 | 2019 | 276 | 0.300 |
Why?
|
| Aged | 10 | 2025 | 13358 | 0.300 |
Why?
|
| Furosemide | 2 | 2018 | 17 | 0.280 |
Why?
|
| Sodium | 2 | 2023 | 60 | 0.270 |
Why?
|
| Diuretics | 2 | 2018 | 58 | 0.270 |
Why?
|
| Male | 16 | 2025 | 27582 | 0.260 |
Why?
|
| Glucose | 2 | 2023 | 444 | 0.240 |
Why?
|
| Troponin I | 2 | 2023 | 32 | 0.240 |
Why?
|
| Biomarkers | 5 | 2023 | 1198 | 0.230 |
Why?
|
| Heart Diseases | 2 | 2024 | 204 | 0.230 |
Why?
|
| Smartphone | 1 | 2025 | 64 | 0.230 |
Why?
|
| Peripartum Period | 1 | 2024 | 31 | 0.230 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2024 | 93 | 0.220 |
Why?
|
| Troponin T | 2 | 2023 | 23 | 0.220 |
Why?
|
| Dyspnea | 1 | 2024 | 108 | 0.210 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2023 | 35 | 0.210 |
Why?
|
| Focus Groups | 1 | 2024 | 293 | 0.210 |
Why?
|
| Heart Ventricles | 2 | 2023 | 251 | 0.210 |
Why?
|
| Electrocardiography | 2 | 2024 | 524 | 0.210 |
Why?
|
| Catheter Ablation | 1 | 2024 | 140 | 0.200 |
Why?
|
| Sterilization, Reproductive | 1 | 2022 | 7 | 0.200 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 188 | 0.200 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 265 | 0.190 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2021 | 7 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2023 | 146 | 0.190 |
Why?
|
| Atherosclerosis | 1 | 2022 | 147 | 0.190 |
Why?
|
| Vital Signs | 1 | 2021 | 11 | 0.180 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 98 | 0.180 |
Why?
|
| Needs Assessment | 1 | 2022 | 191 | 0.180 |
Why?
|
| Asthma | 1 | 2024 | 419 | 0.180 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 36 | 0.170 |
Why?
|
| Stress, Psychological | 1 | 2024 | 444 | 0.170 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 24 | 0.170 |
Why?
|
| Dietary Proteins | 1 | 2019 | 55 | 0.160 |
Why?
|
| Aortic Valve | 1 | 2021 | 170 | 0.160 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 143 | 0.160 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 76 | 0.160 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 98 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 263 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 555 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 567 | 0.160 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 172 | 0.150 |
Why?
|
| Curriculum | 1 | 2022 | 555 | 0.150 |
Why?
|
| Dopamine | 1 | 2018 | 102 | 0.150 |
Why?
|
| Uric Acid | 2 | 2015 | 49 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2024 | 6013 | 0.140 |
Why?
|
| Triage | 1 | 2018 | 110 | 0.140 |
Why?
|
| Atrial Appendage | 1 | 2017 | 28 | 0.140 |
Why?
|
| Coronary Circulation | 1 | 2017 | 50 | 0.140 |
Why?
|
| Sleep | 1 | 2019 | 219 | 0.140 |
Why?
|
| Sarcoidosis | 1 | 2017 | 28 | 0.130 |
Why?
|
| Myocarditis | 1 | 2017 | 61 | 0.130 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 246 | 0.130 |
Why?
|
| Infant | 3 | 2023 | 1524 | 0.120 |
Why?
|
| Gout Suppressants | 1 | 2015 | 25 | 0.120 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 40 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 221 | 0.120 |
Why?
|
| Infant, Newborn | 2 | 2023 | 1306 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 249 | 0.110 |
Why?
|
| Hyperuricemia | 1 | 2013 | 8 | 0.110 |
Why?
|
| Receptors, Opioid | 1 | 2012 | 14 | 0.100 |
Why?
|
| Clonidine | 1 | 2012 | 24 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2021 | 5180 | 0.100 |
Why?
|
| Narcotics | 1 | 2012 | 50 | 0.100 |
Why?
|
| Oxycodone | 1 | 2012 | 32 | 0.100 |
Why?
|
| Analgesics | 1 | 2012 | 100 | 0.100 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2012 | 47 | 0.100 |
Why?
|
| Obesity | 1 | 2019 | 1186 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2018 | 1915 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2013 | 159 | 0.090 |
Why?
|
| Comorbidity | 2 | 2013 | 1090 | 0.090 |
Why?
|
| Disease Progression | 1 | 2015 | 1048 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 152 | 0.080 |
Why?
|
| Prevalence | 3 | 2024 | 1286 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 798 | 0.080 |
Why?
|
| Cytokines | 1 | 2012 | 907 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 41 | 0.080 |
Why?
|
| Stroke | 1 | 2017 | 1138 | 0.080 |
Why?
|
| Diet | 2 | 2023 | 634 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 99 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 496 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1226 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2008 | 156 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 5100 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2008 | 461 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2011 | 1836 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2011 | 2443 | 0.060 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 2004 | 14 | 0.060 |
Why?
|
| Peptide Nucleic Acids | 1 | 2004 | 17 | 0.060 |
Why?
|
| Pericardial Effusion | 1 | 2024 | 16 | 0.060 |
Why?
|
| Home Care Services | 1 | 2025 | 101 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 112 | 0.050 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.050 |
Why?
|
| Hospitalization | 2 | 2025 | 1287 | 0.050 |
Why?
|
| Apoptosis | 1 | 2008 | 1038 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 96 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 142 | 0.050 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 88 | 0.050 |
Why?
|
| Heart Atria | 1 | 2023 | 138 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 95 | 0.050 |
Why?
|
| Vegetables | 1 | 2022 | 91 | 0.050 |
Why?
|
| Child | 1 | 2011 | 4313 | 0.050 |
Why?
|
| Systole | 1 | 2021 | 109 | 0.040 |
Why?
|
| Adolescent | 1 | 2011 | 5922 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2020 | 72 | 0.040 |
Why?
|
| Smoking | 1 | 2024 | 829 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 90 | 0.040 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 10 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 148 | 0.040 |
Why?
|
| Creatinine | 1 | 2018 | 123 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 169 | 0.040 |
Why?
|
| Contraindications, Drug | 1 | 2017 | 1 | 0.040 |
Why?
|
| Nitrogen Radioisotopes | 1 | 2017 | 16 | 0.040 |
Why?
|
| Hyperemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 432 | 0.030 |
Why?
|
| Ammonia | 1 | 2017 | 15 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 69 | 0.030 |
Why?
|
| Vasodilation | 1 | 2017 | 38 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 42 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 80 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 206 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 658 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 141 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2017 | 51 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1104 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 172 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2329 | 0.030 |
Why?
|
| Therapeutics | 1 | 2015 | 7 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 303 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 447 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1029 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 155 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 299 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2017 | 485 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 925 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 796 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2012 | 174 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3102 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2015 | 425 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2012 | 120 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1463 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 807 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3583 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 11 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 104 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 260 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 181 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 454 | 0.020 |
Why?
|
| Caspases | 1 | 2008 | 164 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 448 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2008 | 506 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 594 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 859 | 0.020 |
Why?
|
| Mitochondria | 1 | 2008 | 337 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2008 | 603 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 941 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 853 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1553 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 792 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 2888 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 10273 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 19654 | 0.010 |
Why?
|